Spots Global Cancer Trial Database for Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma

Study Description

Brief Summary: Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) combination is considered as the new gold standard for the first-line treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL). The study is aimed to evaluate the overall response rate and the safety of four cycles of R-CHOP chemotherapy and followed by rituximab augmentation (weekly four times infusion) in newly diagnosed DLBCL patients with aged more than 70 years.

Detailed Description: 1. Four cycles of R-CHOP chemotherapy for the induction treatment \[Dose intensity of CHOP chemotherapy is modulated according to Charlson Comorbidity Index (CCI)\] If patients with CCI \<1 * Rituximab: 375 mg/m2, day 1 every 3 weeks. * Conventional dose of CHOP chemotherapy repeat every 3 weeks. If patients with CCI ≥1 * Rituximab: 375 mg/m2, day 1 every 3 weeks. * 75% of conventional CHOP repeat every 3 weeks. 2. Rituximab augmentation * Rituximab: 375 mg/m2, every week x 4 times. * Trimethoprim-sulfamethoxazole 1 tablet per day during augmentation

Keywords

Eligibility

Minimum Age: 70 Years

Eligible Ages: OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial